Shedir Pharma Srl Unipersonale
MIL:SHE

Watchlist Manager
Shedir Pharma Srl Unipersonale Logo
Shedir Pharma Srl Unipersonale
MIL:SHE
Watchlist
Price: 4.86 EUR Market Closed
Market Cap: 55.2m EUR
Have any thoughts about
Shedir Pharma Srl Unipersonale?
Write Note

Shedir Pharma Srl Unipersonale
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shedir Pharma Srl Unipersonale
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Shedir Pharma Srl Unipersonale
MIL:SHE
Cost of Revenue
-€23.6m
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Newron Pharmaceuticals SpA
SIX:NWRN
Cost of Revenue
-€462k
CAGR 3-Years
-45%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Cost of Revenue
-€731.6m
CAGR 3-Years
-22%
CAGR 5-Years
-12%
CAGR 10-Years
-8%
P
Pierrel SpA
MIL:PRL
Cost of Revenue
-€9.7m
CAGR 3-Years
-13%
CAGR 5-Years
-8%
CAGR 10-Years
-16%
Friulchem SpA
MIL:FCM
Cost of Revenue
-€21.9m
CAGR 3-Years
-16%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
No Stocks Found

Shedir Pharma Srl Unipersonale
Glance View

Market Cap
55.2m EUR
Industry
Pharmaceuticals

Shedir Pharma Group SpA operates as a holding company which engages in the research and development of nutraceuticals and medical devices. The company is headquartered in Mercato San Severino, Salerno and currently employs 71 full-time employees. The company went IPO on 2019-07-23. The firm markets its products in different forms and under the brand lines Shedir Farmaceutici, Deimos Farmaceutici, Phobos Farmaceutici, Menkar Farmaceutici and Greenplanet Divisione Farmaceutica. Its products cover a wide range of therapeutics areas, such as cardiovascular, dermatology, neurology, urology, gynecology and dental health, among others.

SHE Intrinsic Value
7.24 EUR
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Shedir Pharma Srl Unipersonale's Cost of Revenue?
Cost of Revenue
-23.6m EUR

Based on the financial report for Dec 31, 2023, Shedir Pharma Srl Unipersonale's Cost of Revenue amounts to -23.6m EUR.

What is Shedir Pharma Srl Unipersonale's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-8%

Over the last year, the Cost of Revenue growth was -2%. The average annual Cost of Revenue growth rates for Shedir Pharma Srl Unipersonale have been -10% over the past three years , -8% over the past five years .

Back to Top